Erleada (apalutamide) — Medica
non-metastatic castration-resistant prostate cancer (nmCRPC)
Initial criteria
- age ≥ 18 years
- ONE of the following: (a) used in combination with a gonadotropin-releasing hormone (GnRH) analog OR (b) patient has had a bilateral orchiectomy
Approval duration
1 year